THTX (Theratechnologies, Inc.) Net Profit

THTX (Theratechnologies) - company brandmark

Theratechnologies Inc. (THTX) ensures a steady inflow of funds through the implementation of therapy for people living with HIV, making its cash flows resilient to market volatility. This price chart demonstrates that the current figure is -0.01. The company possesses significant pricing power over its highly specialized products, although government procurement limits partially constrain opportunities for further price increases.

THTX (Theratechnologies Inc.) Net Profit history from 07/04/2022 to 10/11/2025

Analytical breakdowns and data insights for company Theratechnologies (THTX)

- price and consensus price forecast:
Stock Quotes Theratechnologies, Inc|THTX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Theratechnologies, Inc|THTX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Theratechnologies|THTX - Book Capitalization|Market Capitalization to Book Value theratech.com|THTX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Theratechnologies Inc.|THTX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Theratechnologies, Inc.|THTX - Company Total Debt|Debts to Book Capitalization Theratechnologies, Inc|THTX - Company Long-Term Debt|Company Short-Term Indebtedness Theratechnologies|Immediate Liquidity theratech.com
- net income and valuation multiples indicators:
THTX - Net Income
Summary company analysis:Theratechnologies Inc.
Core merchandise of Theratechnologies Inc

This metric accumulates the total daily financial result, reflecting the actual resilience of the business's cash flows. It measures the final net income, allowing for the identification of hidden debt risks behind external growth dynamics. The operating profit of Theratechnologies Inc. (THTX) reveals high margins driven by the absence of generics for HIV medications. This protected niche minimizes pricing pressure from competitors, establishing a stable investment profile for the asset.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN: Net Income|Pharming Corp - Profit After Payment of Taxes|NKTR: Net Profit|upstreambio.com - Final Profit|ZBIO (Zenas Biopharma) - Net Profit|Company Net Income Immunome Inc IMNM|Company Net Income Gossamer Corp (GOSS)|KALV (KalVista Corp) - Final Profit|Net Profit SEPN (Septerna Inc)|Net Profit pieris.com PVLA|SVRA: Net Income|Rigel Pharma - Profit After Payment of Taxes|ANAB: Net Profit|Company Net Income Astria Corp (ATXS)|ENGN (enGene Holdings Inc.) - Net Profit|Net Income rapt.com (RAPT)|Net Profit JBIO|ACRS (Aclaris Therapeutics Inc.) - Final Profit|Company Net Income Kyverna KYTX|TLSA: Company Profit|CABA - Company Net Income|Company Net Income ventyxbio.com|Avalo Therapeutics (AVTX) - Company Net Income|ELDN (Eledon Pharmaceuticals Inc.) - Company Net Income|Company Net Income Agenus Inc|Company Net Income Climb Bio, Inc CLYM|Net Profit ZURA|atyrpharma.com (ATYR) - Annual Net Income|Net Profit ADAG (Adagene Inc.)|Net Financial Result ImageneBio (IMA)|Shattuck Therapeutics - Net Profit|Company Net Income Equillium, Inc.|connectbiopharm.com (CNTB) - Company Net Income|IMUX - Net Financial Result|Net Income ATRA|IFRX: Final Profit|Net Profit XFOR|Net Financial Result adicetbio.com|Company Net Income Celularity CELU|INMB: Company Profit|Barinthus Biotherapeutics plc - Net Profit|Kezar Life Sciences Inc. (KZR) - Net Income|SABS (SAB Biotherapeutics, Inc) - Net Income|AKTX - Net Financial Result|Net Income ENLV|QTTB (Q32 Bio Corp) - Profit After Payment of Taxes|Net Profit GOVX|EDSA (Edesa Biotech Inc) - Final Profit|iBio Corp - Net Income|Profit After Payment of Taxes CARM (Carisma Therapeutics Inc)|XTLB: Net Income|BOLT (Bolt Biotherapeutics) - Company Profit|hcwbiologics.com (HCWB) - Company Net Income|Profit After Tax APVO (Aptevo Therapeutics Inc.)|AIM (AIM ImmunoTech) - Net Profit|ADTX: Final Profit|Net Profit GRI|Net Profit xortx.com (XRTX)|Company Net Income Vyome Holdings HIND|Final Profit REVB|INDP - Company Net Income|BiondVax Pharmaceuticals (SCNI) - Net Income|CALI: Net Profit|Affimed N.V. (AFMD) - Net Profit|Net Income ALLK|HOOK: Final Profit|Net Profit IGMS|Net Financial Result iTeos Pharma|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP - Net Income|THRD - Company Net Income